<DOC>
	<DOC>NCT02985983</DOC>
	<brief_summary>To evaluate the efficacy of KHK4827 in axSpA (ankylosing spondylitis [AS] and non-radiographic axial spondyloarthritis [nr-axSpA]) subjects compared to placebo, as measured by the proportion of axSpA subjects achieving an Assessment of SpondyloArthritis international Society (ASAS) 40 response at week 16.</brief_summary>
	<brief_title>A Study of KHK4827 in Subjects With Axial Spondyloarthritis (axSpA)</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<criteria>Clinical diagnosis of axSpA Subject fulfills the ASAS classification criteria of axial Spondyloarthritis (with the exception of the Crohn's disease criterion) for &gt; 3 months Subject has Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at screening and enrollment Subject has spinal pain score (BASDAI question #2) ≥ 4 at screening and enrollment Subject has had adequate therapy of nonsteroidal antiinflammatory drugs (NSAIDs) for at least 3 months. Complete ankylosis (fusion) of the spine Subject with active ongoing inflammatory diseases other than axSpA that might confound the evaluation of KHK4827 therapy, including reactive arthritis, spondyloarthritis associated with inflammatory bowel disease, SAPHO syndrome (pustulotic arthroosteitis), fibromyalgia, ankylosing spinal hyperostosis, osteitis condensans ilii, spondylosis deformans, or osteoarthritis sacroiliac joint disease Subject has a prior history of &gt;1 antiTNF therapy for axSpA Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the ColumbiaSuicide Severity Rating Scale (CSSRS) at enrollment Subject has a history or evidence of a psychiatric disorder, alcohol and/or substance abuse, or any other mental health disorder that, in the opinion of the investigators, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion Subject has severe depression based on a total score of ≥ 15 on the Patient Health Questionnaire8 (PHQ8) at enrollment (note: subjects with a total score of 10 to 14 on the PHQ8 should be referred to a mental health care professional).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Brodalumab</keyword>
	<keyword>KHK4827</keyword>
	<keyword>Axial Spondyloarthritis</keyword>
</DOC>